


## PHARMACEUTICAL 2019

## UroGen Pharma Ltd. Rank 268 of 371







## PHARMACEUTICAL 2019

## UroGen Pharma Ltd. Rank 268 of 371



The relative strengths and weaknesses of UroGen Pharma Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of UroGen Pharma Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 221% points. The greatest weakness of UroGen Pharma Ltd. is the variable Net Income, reducing the Economic Capital Ratio by 216% points.

The company's Economic Capital Ratio, given in the ranking table, is -356%, being 24% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	102,243
Cost of Goods Sold	1,803
Intangible Assets	0
Liabilities, Current	13,465
Liabilities, Non-Current	0
Other Assets	368
Other Compr. Net Income	0
Other Expenses	37,059
Other Liabilities	0
Other Net Income	1,648
Property and Equipment	948
Research and Development	0
Revenues	1,128
Selling, General and Administrative Expense	39,571

Output Variable	Value in 1000 USD
Assets	103,559
Liabilities	13,465
Expenses	78,433
Stockholders Equity	90,094
Net Income	-75,657
Comprehensive Net Income	-75,657
Economic Capital Ratio	-356%